DCF Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

DCF Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.62M	Sell	254,500 -45,500	-15%	-$1.52M	1.52%	11
2026 Q1	$9.04M	Sell	300,000 -85,000	-22%	-$2.73M	2.41%	8
2025 Q4	$12M	Buy	385,000 +17,300	+5%	+$426K	3.22%	4
2025 Q3	$7.43M	Buy	367,700 +185,200	+101%	+$3.25M	2.39%	7
2025 Q2	$3.06M	Buy	182,500 +11,500	+7%	+$186K	1.42%	27
2025 Q1	$2.63M	Buy	171,000 +23,500	+16%	+$420K	1.26%	28
2024 Q4	$3.25M	Buy	147,500 +34,500	+31%	+$628K	1.57%	22
2024 Q3	$2.04M	Sell	113,000 -17,750	-14%	-$311K	0.81%	30
2024 Q2	$2.12M	Buy	130,750 +45,750	+54%	+$705K	1.09%	29
2024 Q1	$1.2M	Buy	85,000 +46,000	+118%	+$580K	0.59%	41
2023 Q4	$407K	Sell	39,000 -5,500	-12%	-$51.4K	0.22%	62
2023 Q3	$454K	Buy	44,500 +5,500	+14%	+$51.2K	0.25%	66
2023 Q2	$294K	Buy	+39,000	New	+$316K	0.16%	76

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

DCF Advisers's TEVA Position: Q2 2026 in Review

DCF Advisers reduced its Teva Pharmaceuticals (TEVA) stake by 15% in Q2 2026, selling an estimated $1.52M and leaving 254,500 shares worth $8.62M. The position accounts for 1.52% of the portfolio, ranked #11.

DCF Advisers first reported a position in TEVA in Q2 2023 and has held it in 13 quarters since. The position peaked at $12M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

DCF Advisers held 254,500 shares of Teva Pharmaceuticals worth $8.62M as of Q2 2026.
DCF Advisers sold 45,500 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.52M.
Teva Pharmaceuticals made up 1.52% of DCF Advisers's portfolio in Q2 2026, its #11 holding.
DCF Advisers first reported a position in Teva Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
DCF Advisers's Teva Pharmaceuticals position peaked at $12M in Q4 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.